Efficacy and safety of anti-interleukin-20 monoclonal antibody in patients with rheumatoid arthritis: A randomized phase IIa trial

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1438-1448

  Šenolt, Ladislav ^a   Leszczynski, Piotr ^b   Dokoupilová, Eva ^c   Göthberg, Marie ^d   Valencia, Xavier ^e   Hansen, Brian Bekker ^d   Cañete, Juan D ^f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Sro   (Czech Republic)

^d NOVO NORDISK A S   (Denmark)

^e NOVO NORDISK INC   (United States)

^f HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; FLETIKUMAB; INTERLEUKIN 20; METHOTREXATE; RHEUMATOID FACTOR; STROMELYSIN; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ANEMIA; ARTICLE; BONE PAIN; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HERPES SIMPLEX; HUMAN; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; CLINICAL TRIAL; IMMUNOLOGY; MALE; MULTICENTER STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HERPES SIMPLEX; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; NASOPHARYNGITIS; PEPTIDES, CYCLIC; RESPIRATORY TRACT INFECTIONS; RHEUMATOID FACTOR; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84929849291     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39083     Document Type: Article

References (35)

1. McInnes IB, Schett G., The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
2. Schoels M, Aletaha D, Smolen JS, Wong JB., Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71: 1303-8.
3. Senolt L, Vencovsky J, Pavelka K, Ospelt C, Gay S., Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009; 9: 102-7.
4. Burmester GR, Feist E, Dorner T., Emerging cell and cytokine targets in rheumatoid arthritis. Nat Rev Rheumatol 2014; 10: 77-88.
5. Hsu YH, Li HH, Hsieh MY, Liu MF, Huang KY, Chin LS, et al., Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006; 54: 2722-33.
6. Kragstrup TW, Otkjaer K, Holm C, Jorgensen A, Hokland M, Iversen L, et al., The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine 2008; 41: 16-23.
7. Romer J, Jackerott M, Mandelbaum J, Andersen M, Nielsen NS, Bliddal H., Expression of interleukin-20 and its receptor chains IL-20R1, IL-20R2 and IL-22R in synovium from patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2012; 71 Suppl 3: 646.
8. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, et al., Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006; 15: 991-1004.
9. Otkjaer K, Kragballe K, Johansen C, Funding AT, Just H, Jensen UB, et al., IL-20 gene expression is induced by IL-1β through mitogen-activated protein kinase and NF-κB-dependent mechanisms. J Invest Dermatol 2007; 127: 1326-36.
10. Chen WY, Chang MS., IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol 2009; 182: 5003-12.
11. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, et al., Interleukins 19, 20, and 24 signal through two distinct receptor complexes: differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002; 277: 47517-23.
12. Wegenka UM., IL-20: biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev 2010; 21: 353-63.
13. Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS., Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med 2011; 208: 1849-61.
14. Romer J, Lebre MC, Jonckheere CL, Fjording M, Frederiksen KS, Tak PP., IL-20 is present in rheumatoid arthritis synovial membranes and anti-IL-20 prevents upregulation of CCL2, CCL4, CCL5, and CCR7 ex vivo [abstract]. Ann Rheum Dis 2009; 68 Suppl 3: 83.
15. Hsu YH, Chang MS., Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum 2010; 62: 3311-21.
16. Leszczynski P, Eshof M, Stegmann H, Hundahl Moller N, Graff LB., FRI0197 NNC0109-0012 (anti-IL-20 mAb), well tolerated in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2012; 71 Suppl 3: 379-80.
17. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. URL: http://www.wma.net/en/30publications/10policies/b3/17c.pdf.
18. International Conference on Harmonisation. ICH harmonised tripartite guideline: guideline for good clinical practice E6 (R1). June 1996. URL: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
20. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al., Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
21. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al., The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-40.
22. Kuriya B, Sun Y, Boire G, Haraoui B, Hitchon C, Pope JE, et al., Remission in early rheumatoid arthritis: a comparison of new ACR/EULAR remission criteria to established criteria. J Rheumatol 2012; 39: 1155-8.
23. Siegel JN, Zhen BG., Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in favor. Arthritis Rheum 2005; 52: 1637-41.
24. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL., Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
25. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
26. Stanford University Medical Center. ARAMIS: HAQ. URL: http://aramis.stanford.edu/HAQ.html.
27. Fries JF, Spitz P, Kraines RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
28. Anderson JK, Zimmerman L, Caplan L, Michaud K,. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken) 2011; 63 Suppl 11: S14-36.
29. Bobbio-Pallavicini F, Caporali R, Alpini C, Avalle S, Epis OM, Klersy C, et al., High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor α inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 302-7.
30. Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, et al., Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 497-500.
31. Hyrich KL, Watson KD, Silman AJ, Symmons DP, and, the BSR, Biologics Register. Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-65.
32. Morozzi G, Fabbroni M, Bellisai F, Cucini S, Simpatico A, Galeazzi M., Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 2007; 26: 1335-8.
33. Van den Broek M, Dirven L, Klarenbeek NB, Molenaar TH, Han KH, Kerstens PJ, et al., The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Ann Rheum Dis 2012; 71: 245-8.
34. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al., Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72: 329-36.
35. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al., Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122: 1791-802.